| 114.03 4.41 (4.02%) | 08-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 140.86 |
1-year : | 164.52 |
| Resists | First : | 120.59 |
Second : | 140.86 |
| Pivot price | 107.27 |
|||
| Supports | First : | 107.57 |
Second : | 99.51 |
| MAs | MA(5) : | 109.23 |
MA(20) : | 108.68  |
| MA(100) : | 92.8 |
MA(250) : | 77.32 |
|
| MACD | MACD : | 1 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 74.9 |
D(3) : | 58.9 |
| RSI | RSI(14): 61.1 |
|||
| 52-week | High : | 130.05 | Low : | 39.84 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KYMR ] has closed Bollinger Bands are 21.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 115.06 - 115.4 | 115.4 - 115.78 |
| Low: | 108.08 - 108.48 | 108.48 - 108.94 |
| Close: | 113.29 - 113.92 | 113.92 - 114.63 |
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Wed, 12 Aug 2026
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Tue, 11 Aug 2026
Kymera Therapeutics (NASDAQ:KYMR) Sees Unusually-High Trading Volume - Still a Buy? - marketbeat.com
Sat, 08 Aug 2026
California State Teachers Retirement System Increases Stake in Kymera Therapeutics, Inc. $KYMR - marketbeat.com
Thu, 06 Aug 2026
Kymera Therapeutics (KYMR) Stock Faces A Revenue Durability Reckoning - simplywall.st
Wed, 05 Aug 2026
Kymera Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:KYMR) 2026-08-05 - Seeking Alpha
Wed, 05 Aug 2026
Is Kymera Therapeutics Inc (KYMR) Overvalued After Q2 Earnings B - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 82 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 115.6 (%) |
| Shares Short | 9,900 (K) |
| Shares Short P.Month | 9,960 (K) |
| EPS | -3.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.22 |
| Profit Margin | -285.4 % |
| Operating Margin | -116.4 % |
| Return on Assets (ttm) | -15.6 % |
| Return on Equity (ttm) | -24.2 % |
| Qtrly Rev. Growth | 466.3 % |
| Gross Profit (p.s.) | -3.29 |
| Sales Per Share | 1.27 |
| EBITDA (p.s.) | -4.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -237 (M) |
| Levered Free Cash Flow | -144 (M) |
| PE Ratio | -35.09 |
| PEG Ratio | 0 |
| Price to Book value | 6.25 |
| Price to Sales | 89.33 |
| Price to Cash Flow | -39.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|